Payment overview · 2025
General Payments
$7,934.25
78 reported records · 31 companies
Healthcare provider profile · identity verified
Zabila Saeed, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NORTON SHORES, MI · NPI 1578084232
Verified facts
What the public records show
CMS Open Payments records show Zabila Saeed, MD received $7,934.25 in general payments during 2025 across 78 reported records.
Ipsen Biopharmaceuticals, Inc accounted for 75.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $5,963.17 | 75.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.39 | 3.0% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $225.56 | 2.8% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $144.80 | 1.8% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $113.58 | 1.4% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $110.43 | 1.4% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $101.35 | 1.3% | 3 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $100.00 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $85.17 | 1.1% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $83.03 | 1.1% | 3 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $76.79 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $63.89 | 0.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.63 | 0.8% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $54.47 | 0.7% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $47.24 | 0.6% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $41.97 | 0.5% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.88 | 0.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $39.56 | 0.5% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $38.28 | 0.5% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.22 | 0.4% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $35.06 | 0.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.53 | 0.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.83 | 0.3% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $27.58 | 0.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.31 | 0.3% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $24.32 | 0.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.89 | 0.3% | 1 | 2025 |
| Menarini Silicon Biosystems, Inc. | Unresolved — no canonical attribution shown | $20.98 | 0.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.56 | 0.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $16.08 | 0.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $14.70 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,600.00 | 1 |
| Food and Beverage | $2,018.98 | 76 |
| Travel and Lodging | $315.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $5,963.17 | 3 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $225.56 | 8 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $144.80 | 5 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $113.58 | 4 | 2025 |
Source payment records
|
|||||
| ILLUCCIX Normalized: illuccix |
Drug | Telix Pharmaceuticals | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $92.28 | 3 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $85.17 | 4 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $83.03 | 3 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $76.79 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $67.70 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $63.89 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $56.15 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $51.16 | 2 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $39.56 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $36.52 | 2 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.65 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $32.53 | 1 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Cellsearch Normalized: cellsearch |
Device | Menarini Silicon Biosystems, Inc. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prochlorperazine Maleate | Prochlorperazine Maleate | 104 | 69 |
| Potassium Chloride | Potassium Chloride | 77 | 29 |
| Prednisone | Prednisone | 48 | 27 |
| Ondansetron Odt | Ondansetron | 47 | 35 |
| Imatinib Mesylate | Imatinib Mesylate | 44 | suppressed |
| Eliquis | Apixaban | 42 | 16 |
| Furosemide | Furosemide | 41 | 22 |
| Olanzapine | Olanzapine | 38 | 21 |
| Creon | Lipase/Protease/Amylase | 33 | 13 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | 23 |
| Gabapentin | Gabapentin | 26 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 25 | suppressed |
| Nyvepria | Pegfilgrastim-Apgf | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | 11 |
| Lonsurf | Trifluridine/Tipiracil Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 14 |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 16 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Neulasta | Pegfilgrastim | 13 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sunitinib Malate | Sunitinib Malate | 12 | suppressed |
| Zarxio | Filgrastim-Sndz | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,934.25 · 78 records | Ipsen Biopharmaceuticals, Inc | ALYMSYS, BENEFIX, BRUKINSA, CABOMETYX, CARVYKTI, Cellsearch, DARZALEX, DATROWAY, ENHERTU, EPKINLY, ERLEADA, FRUZAQLA, Fabhalta, HYMPAVZI, ICLUSIG, ILLUCCIX, IMFINZI, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LYNPARZA, Lenvima, MI CANCER SEEK, MONJUVI, OPDIVO, ORGOVYX, Onivyde, POTELIGEO, PYRUKYND, QINLOCK, RYBREVANT, RYTELO, TECVAYLI, TEVIMBRA, Trodelvy, VENCLEXTA, VERZENIO, XPOVIO, XYNTHA, ZEJULA, ZEPZELCA, ZYNYZ | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error